Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Four Week Study of the Efficacy and Safety of Four Doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of Aplindore MR Tablets vs. Placebo in Idiopathic Restless Legs Syndrome.
NCT00834327 is registered in ClinicalTrials.gov with Neurogen Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Four Week Study of the Efficacy and Safety of Four Doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of Aplindore MR Tablets vs. Placebo in Idiopathic Restless Legs Syndrome.
- Lead sponsor
- Neurogen Corporation
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 28, 2009
- Completion date
- December 31, 2009
- Enrollment
- 230 (estimated)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.